Companies /Healthcare
Syndax Pharmaceuticals Inc
NASDAQ: SNDX Biotechnology
$8.56
▼ $0.64 (−6.96%) today
Markets closed · 2:11am ET

Syndax Pharmaceuticals (SNDX) Q3 2026 Earnings

Reported Nov 2, 2026, 4:02pm ET · SEC source
$-0.55
Miss −12.89%
EPS · est. $-0.49 GAAP
$83.3M
Beat +1.68%
Revenue · est. $81.9M
2 quarters
Consecutive EPS misses

How Did SNDX Stock React to Q3 2026 Earnings?

% change · around the report
0+4%+8%+12%Nov 2Nov 3report 4:02pm ETearnings+0.3%+11.7%
0+4%+8%+12%Nov 2Nov 3earnings+0.3%+11.7%
SNDX +11.7%S&P 500 +0.3%
0+4%+8%+12%Nov 2Nov 3report 4:02pm ETearnings+0.5%+11.7%
0+4%+8%+12%Nov 2Nov 3earnings+0.5%+11.7%
SNDX +11.7%NASDAQ +0.5%
+9.08%
Day of report
−26.87%
Next session
−33.59%
One week

Did SNDX Beat Earnings? Q3 2026 Results

No. Syndax Pharmaceuticals reported Q3 2026 earnings of $-0.55 a share on Nov 2, 2026, missing the $-0.49 consensus estimate by 12.9%. Revenue was $83.3M against a $81.9M estimate.

Syndax Pharmaceuticals delivered a mixed third quarter for fiscal 2026, beating on revenue while falling short on the bottom line. Total revenue reached $83.30 million, ahead of the $81.92 million consensus by 1.68% and up 81.6% year over year, propelled by continued commercial momentum from its two marketed medicines. Revuforj net product revenue of $60.74 million, growing 90% year over year, was the primary engine, with the quarter marking the seventh consecutive period of double-digit sequential growth in both net revenue and total prescriptions, including roughly 1,700 total prescriptions and approximately 300 new patient starts. Yet higher costs tied to frontline revumenib combination trials pushed R&D expense to $67.48 million, widening the GAAP loss per share to $0.55 against a consensus estimate of $0.49, a miss of 12.89%. Management reiterated full-year operating expense guidance of approximately $400 million, excluding roughly $50 million in non-cash stock compensation, and said existing cash of $551.08 million combined with growing product and collaboration revenue should carry the company to profitability.

Key Takeaways
  • Revuforj new patients up ~20% q/q and total prescriptions up ~13% q/q
  • Growing number of R/R KMT2Ar and NPM1m patients resuming Revuforj after stem cell transplant
  • ~50% of R/R KMT2Ar patients proceed to HSCT, of whom ~60% resume therapy; ~40% of NPM1m patients proceed to HSCT, of whom ~50% resume
  • More than 35% of 3Q26 Revuforj net revenue from the NPM1 business
  • Niktimvo net revenue of $67.4M, up 47% y/y, with >300 new patients and ~6,350 infusions in 3Q26
  • Payer coverage of 99% of covered lives; >620 total accounts activated (+8% q/q)
  • SG&A down y/y as 2025 launch costs did not recur

“We delivered another quarter of strong commercial results, generating $83 million in total revenue to Syndax. Revuforj net revenue grew to $61 million, driven by a 20% increase in new patients and an increasing number of patients on therapy in the post-transplant setting.”

Syndax Pharmaceuticals CEO, on the earnings call

What Is Syndax Pharmaceuticals's Outlook?

Syndax continues to expect full-year 2026 R&D plus SG&A expenses of approximately $400 million, excluding approximately $50 million in estimated non-cash stock compensation. It expects its cash, cash equivalents and investments, combined with product revenue, collaboration revenue and interest income, to enable it to reach profitability. Management estimates U.S. peak annual net revenue potential for Revuforj of $2B+, including anticipated frontline indications. It says Niktimvo collaboration revenue is annualizing at $90M+.

SNDX YoY Financials

Q3 2026 vs Q3 2025 · SEC filings Q3 2025 Q3 2026
$-40,000,000$0$40.0M$80.0M$45.9M$83.3MRevenue$-32,975,207$-41,895,000Operating Income$-41,687,468$-49,433,000Net Income
$-40,000,000$0$40.0M$80.0MRevenueOperating IncomeNet Income
SNDX income statement, Q3 2026 versus Q3 2025
Metric Q3 2026 Q3 2025 Year over year
Revenue $83.3M $45.9M +81.6%
Operating Income −$41.9M −$33.0M +27.1%
Net Income −$49.4M −$41.7M +18.6%

SNDX Revenue by Segment

Revuforj (revumenib)$60.7M+90.0%
Niktimvo (axatilimab-csfr) - Collaboration Revenue$22.6M+63.0%
Niktimvo (axatilimab-csfr) - collaboration revenue
Niktimvo (axatilimab-csfr)
Milestone, License and Royalty Revenue

Figures from SEC filings and company reports. Not investment advice.